What is the recommended management for a patient with viral pneumonia caused by influenza and COVID-19?

Management of Viral Pneumonia Caused by Influenza and COVID-19

For patients with confirmed COVID-19 pneumonia, empirical antibacterial coverage is not routinely required unless there is clinical suspicion of bacterial co-infection, whereas patients with influenza pneumonia should receive antiviral therapy with oseltamivir within 48 hours of symptom onset, and both conditions require oxygen support and corticosteroids when hypoxemia is present. 1, 2

Antiviral Therapy

COVID-19 Specific Treatment

• Corticosteroids are strongly recommended for patients requiring supplemental oxygen, noninvasive ventilation, or invasive mechanical ventilation 1
• Do NOT use corticosteroids in hospitalized COVID-19 patients who do not require supplemental oxygen 1
• IL-6 receptor antagonist therapy (tocilizumab) should be considered for patients requiring oxygen or ventilatory support 1
• Remdesivir has no clear recommendation for patients not requiring invasive mechanical ventilation; it is conditionally recommended AGAINST in patients requiring invasive mechanical ventilation 1

Influenza Specific Treatment

• Oseltamivir should be administered within 48 hours of symptom onset for severe influenza illness 2
• Baloxavir is conditionally recommended for patients at high risk of progression from non-severe to severe illness 2
• Neuraminidase inhibitors have proven efficacy in reducing need for ventilatory support and mortality 3

Co-infection Considerations

• Co-infected patients with both influenza and COVID-19 show elevated risk for poor outcomes compared to mono-infected patients 4
• Screen high-risk COVID-19 patients for influenza given the 15.7% poor outcome rate (death/deterioration) in co-infected patients 4
• Most common complications include pneumonia, linear atelectasis, and acute respiratory distress syndrome 4

Antibacterial Coverage Strategy

When to Withhold Antibiotics

• Empirical antibacterial coverage is NOT required in all patients with confirmed COVID-19 pneumonia 1
• Use procalcitonin levels to guide withholding or early stopping of antibiotics, especially in less severe disease 1
• Low procalcitonin values early in confirmed COVID-19 illness support withholding antibiotics 1

When to Initiate Antibiotics

For patients WITHOUT confirmed COVID-19 diagnosis:

• Empirical antibacterial coverage is recommended for all patients with community-acquired pneumonia 1

For patients WITH confirmed COVID-19 who have:

• Clinical suspicion of bacterial co-infection 1
• Severe pneumonia requiring ICU admission 1
• Known history of multidrug-resistant pathogens 1

Antibiotic Regimens

Low-risk inpatients (general medical floor):

• β-lactam (ampicillin-sulbactam, ceftriaxone, or cefotaxime) PLUS macrolide (azithromycin or clarithromycin) OR doxycycline 1
• Alternative: Respiratory fluoroquinolone monotherapy (levofloxacin or moxifloxacin) 1

High-risk inpatients (ICU):

• β-lactam PLUS macrolide 1
• Alternative: β-lactam PLUS fluoroquinolone 1

For severe influenza pneumonia:

• Parenteral broad-spectrum β-lactamase stable antibiotic (co-amoxiclav or second/third generation cephalosporin) PLUS macrolide 1
• Alternative: Fluoroquinolone with enhanced pneumococcal activity PLUS broad-spectrum β-lactam or macrolide 1

Target Pathogens

The bacterial pathogens in COVID-19 and influenza pneumonia are the same as typical community-acquired pneumonia: Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, and Staphylococcus aureus 1

Microbiological Testing

• Obtain blood and sputum cultures when there is concern for multidrug-resistant pathogens (Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus) 1
• If cultures are negative and patient is improving, narrow expanded antibiotic therapy within 48 hours 1
• Consider MRSA coverage in patients hospitalized within the last few months who have suspected staphylococcal pneumonia or are not responding to empirical therapy 1

Duration of Antibiotic Therapy

• 5 days of antibiotic therapy is adequate for most patients with community-acquired pneumonia 1
• Switch from IV to oral antibiotics when clinical improvement occurs and temperature has been normal for 24 hours 1

Therapies to AVOID

Strong recommendations AGAINST:

• Hydroxychloroquine for any COVID-19 patient 1
• Lopinavir-ritonavir for hospitalized COVID-19 patients 1
• Antibiotics in non-severe influenza without bacterial infection 1

Conditional recommendations AGAINST:

• Azithromycin in hospitalized COVID-19 patients without bacterial infection 1
• Hydroxychloroquine and azithromycin combination 1
• Colchicine for hospitalized COVID-19 patients 1
• Interferon-β for hospitalized COVID-19 patients 1
• Corticosteroids in severe influenza pneumonia 1

Supportive Care

Respiratory Support

• High-flow nasal cannula (HFNC) or noninvasive CPAP (helmet or facemask) for hypoxemic acute respiratory failure without immediate indication for invasive mechanical ventilation 1
• Prone positioning should be applied early in severe ARDS (PaO₂/FiO₂ ≤100 mm Hg) 1
• Limit tidal volumes ≤6 mL/kg predicted body weight and plateau pressure ≤30 cm H₂O 1

Anticoagulation

• Strongly recommend offering anticoagulation to all hospitalized COVID-19 patients 1

Additional Supportive Measures

• Protocolized light sedation 1
• Enteral nutrition and glycemic control 1
• Deep vein thrombosis prophylaxis 1
• Stress ulcer prophylaxis 1

Critical Pitfalls to Avoid

• Do not routinely prescribe antibiotics for confirmed COVID-19 pneumonia without evidence of bacterial co-infection—this drives antimicrobial resistance 1, 5
• Do not delay oseltamivir beyond 48 hours in influenza pneumonia—efficacy diminishes significantly 2
• Do not use corticosteroids in COVID-19 patients who are not hypoxemic—this provides no benefit and potential harm 1
• Do not continue broad-spectrum antibiotics beyond 48 hours if cultures are negative and patient is improving 1
• Bacterial co-infection rates in COVID-19 are low despite widespread antibiotic use—diagnostic uncertainty should not drive empirical overtreatment 1, 5